Voncento Safe, Effective in Young Children With Hemophilia A, Trial Finds

Voncento Safe, Effective in Young Children With Hemophilia A, Trial Finds

299317

Voncento Safe, Effective in Young Children With Hemophilia A, Trial Finds

Voncento — a highly concentrated mixture of Von Willebrand factor (VWF) and clotting factor VIII (FVIII) — was seen to safely and effectively treat or prevent bleeds in children, age 12 and younger, with severe hemophilia A, according to data from a Phase 3 trial. Findings were reported in the study “Efficacy, safety and pharmacokinetic results of a phase III, open-label, multicenter study with a plasma-derived von Willebrand factor (VWF)/factor VIII (FVIII) concentrate in pediatric patients…

You must be logged in to read/download the full post.